SCHEMBL4588601

SCHEMBL4588601

C[C@]12CC[C@]3(C=O)c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)C2(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 0.41
ESR2 Q92731 9/20 0.41
HSD17B10 Q99714 4/20 0.38
LMNA P02545 4/20 0.38
NR3C1 P04150 4/20 0.38
HIF1A Q16665 3/20 0.38
SHBG P04278 3/20 0.38
PGR P06401 3/20 0.38
SERPINA6 P08185 3/20 0.38
AR P10275 3/20 0.38
SLC6A4 P31645 3/20 0.38
SNCA P37840 3/20 0.38
SLC6A3 Q01959 3/20 0.38
TSHR P16473 2/20 0.38
CYP1A2 P05177 2/20 0.38
AKR1B10 O60218 2/20 0.38
CYP3A4 P08684 2/20 0.38
STS P08842 2/20 0.38
MAPT P10636 2/20 0.38
AKR1B1 P15121 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4588605 1.00 ESR1 (0.41) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL4588414 0.90 ESR1 (0.41) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL4587569 0.79 ESR1 (0.44) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL4587563 0.79 ESR1 (0.44) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL4587411 0.79 NR3C1 (0.41) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL4587414 0.79 NR3C1 (0.41) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL6233082 0.79 NR3C1 (0.41) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL6233085 0.79 NR3C1 (0.41) ESR1ESR2HSD17B10LMNANR3C1
SCHEMBL4587863 0.75 NR3C1 (0.42) ESR1ESR2NR3C1PGRAR
SCHEMBL6229119 0.70 ESR2 (0.36) ESR1ESR2HSD17B10CYP3A4STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414043-B2 9-α-substituted estratrienes as selectively active estrogens SCHERING AG (DE) 2008-08-19 US disclosed
US-20080132476-A1 SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS KOSEMUND DIRK 2008-06-05 US disclosed
EP-1517914-B1 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN SCHERING AG (DE) 2005-08-31 EP disclosed
EP-1517914-A2 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN Schering Aktiengesellschaft (DE) 2005-03-30 EP disclosed
WO-2003104253-A2 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN SCHERING AKTIENGESELLSCHAFT (DE) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132476-A1 SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS ESRRA, ESR2, ESR1 ESR1 3/4885ESR2 2/4885HSD17B10 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.